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Background: Neuroendocrine Cell Hyperplasia of Infancy (NEHI) and Follicular Bronchiolitis (FB) are rare pediatric
diffuse lung diseases with poorly understood pathogenesis and similar clinical presentations. We sought to
determine if cellular and cytokine profiles in bronchoalveolar lavage fluid (BALF) from subjects with NEHI and FB
would differ from pediatric disease controls.
Methods: BALF was obtained from forty-one subjects classified into four disease groups: NEHI, Cystic Fibrosis (CF),
other airway disease controls (DC), and FB during clinically indicated procedures. BALF cellular profiles and ten
cytokines were measured and values compared across groups using descriptive and nonparametric statistics.
Results: Significant BALF cellular and cytokine differences were seen across all groups. NEHI subjects exhibited the
lowest total absolute white blood cell (WBC) levels with a higher percentage of BALF alveolar macrophages
compared to controls. NEHI also had lower levels of IL-1β, MIP-1β and IL-8 and FB had higher levels of IL-1ra, G-CSF
and VEGF compared to all groups. IL-6 was elevated in CF and FB.
Conclusions: BALF cytokine and cellular profiles differed between NEHI, FB, CF and DC subjects. This pilot data
suggests different and distinguishing inflammatory responses in the airway, with the least inflammatory being NEHI.
These data could have diagnostic implications.
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Children’s interstitial and diffuse lung diseases (chILD)
are a heterogeneous group of rare diseases, characte-
rized by hypoxia, tachypnea, and crackles, in the absence of
other diagnoses. Other findings include diffuse infiltrates
found on radiographic imaging of the chest and disordered
gas exchange [1]. After known causes of lung disease have
been ruled out, this constellation of signs and symptoms
has been labeled children’s interstitial lung disease (chILD)
syndrome [2]. ChILD syndrome includes pulmonary inter-
stitial glycogenosis (PIG), genetic abnormalities of surfac-
tant function, specifically mutations in the surfactant* Correspondence: Jpopler@gppa.net
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reproduction in any medium, provided the orprotein B (SP-B), surfactant protein C (SP-C), NKX2.1,
and ATP-binding cassette transporter (ABCA3) genes,
which predominately involve the interstitium, and neuro-
endocrine cell hyperplasia (NEHI) and follicular bron-
chiolitis (FB) which predominately involve the airways
[2,3]. These diseases are rare, present similarly, and can
often masquerade as other entities, leading to difficult
diagnostic dilemmas in the pediatric population. The
underlying mechanisms of these disorders are incom-
pletely understood.
Neuroendocrine cell hyperplasia of infancy (NEHI) is a
recently described respiratory disorder of unknown eti-
ology characterized clinically by tachypnea, retractions,
crackles and hypoxemia [1]. Recognition of NEHI has in-
creased throughout the medical community [1,4]. No mor-
tality has been reported but most children require several
years of oxygen therapy and nutritional supplementation [5].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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NEHI often presents with a characteristic appearance on
high-resolution computed tomography (HRCT). The pattern
consists of ground glass opacities (GGOs) most commonly
occurring in the right middle lobe and lingula; additionally,
mosaic air trapping is also seen [6,7]. Infant pulmonary func-
tion testing in NEHI has shown evidence of small airway
obstruction and air trapping [4,8,9]. The term “NEHI syn-
drome” is used to indicate a diagnosis of NEHI without
lung biopsy, based on a consistent clinical presentation
and HRCT findings [10,11]. The diagnostic gold standard
is lung biopsy demonstrating increased numbers of
bombesin–immunopositive pulmonary neuroendocrine
cells (PNECs) within bronchioles and alveolar ducts
without evidence of other abnormalities, and limited or
absent inflammation [2].
Despite improved clinical characterization, the underlying
etiology for NEHI is unknown and a genetic defect has not
been reported. However, multiple cases of NEHI have been
found within several families, suggesting the mechanism of
disease may be related to a genetic etiology [12].
Follicular bronchiolitis (FB) is a rare chILD disorder
with a paucity of pediatric literature. In a series of five FB
patients, patients presented with cough, crackles and re-
spiratory distress features that overlap with NEHI. There
was little glucocorticoid responsiveness (13). Histologic
findings were characterized by follicular lymphoid hyper-
plasia around the bronchus and between the bronchiole
and pulmonary artery in all patients. These follicles have
germinal centers and frequently compress the bronchial
lumen. A concentric ring of lymphocytes surrounded the
bronchioles [13].
In patients with chILD syndrome, histopathologic data
suggest that inflammation may be important to the under-
lying pathogenesis of many these disorders, except in
NEHI where few signs of inflammation are seen histologi-
cally. As BALF is less invasive than lung biopsy, we elected
to study cellular and cytokine profiles. Although BALF
cytokine profiles have been investigated in adult interstitial
lung disease (ILD), to our knowledge no similar investiga-
tion has been done within the chILD population [14].
We hypothesized that BALF cellular and cytokine pro-
files in NEHI and FB would differ from profiles in
pediatric airway disease control subjects. Furthermore
we believed that that NEHI would show limited pro-
inflammatory cytokine elevation in contrast to FB and
airway disease controls based upon lung pathology that
has shown limited inflammation and clinical reports of
poor response to glucocorticoids.
Methods
Subjects
The study was designed as a single center descriptive
study to measure cytokine levels in the BALF of childrenwith NEHI and FB compared to disease controls. These
were clinically indicated samples collected from 1998 to
2009. As NEHI and FB are felt to be predominately air-
way related diseases, we chose airway disease control
subjects with cystic fibrosis (CF), bronchiectasis (non-
cystic fibrosis), bronchiolitis obliterans, or suspected as-
piration syndromes as the comparison group.
Within the NEHI group, both patients with biopsy-
proven NEHI (n= 11), as well as patients with NEHI syn-
drome (n=11) were combined. NEHI syndrome subjects
were those who had not undergone lung biopsy, but had
symptoms consistent with NEHI, including tachypnea,
crackles, and desaturation. All NEHI syndrome patients
underwent HRCT with images reviewed by a radiologist
experienced in recognizing NEHI and all had findings
consistent with NEHI including ground glass opacities
(GGO) and air trapping [10-12].
Subjects with FB were diagnosed by lung tissue review
by a pediatric pathologist experienced in identifying the
typical appearance of FB. Disease controls were confirmed
by appropriate clinical presentation and confirmatory test-
ing. CF was diagnosed by sweat test and genotyping. The
diagnosis of non-cystic fibrosis bronchiectasis and bron-
chiolitis obliterans were confirmed by chest CT. Subjects
with suspected aspiration syndromes had confirmatory
testing with swallowing evaluations with oropharyngeal
motility studies.
Disease control subjects also underwent clinically-
indicated bronchoscopy and lavage. If multiple longitu-
dinal dates for BALF sample collection were recorded
from a subject, the first BALF sample with an acceptable
volume percentage was used. Published values for cell
counts and cytology differentials in the BALF of healthy,
non-wheezing children were also used as normal control
reference ranges [15,16].
The study was approved by the University of Colorado
Denver Institutional Review Board. Informed consent
was obtained from all subjects. If the patient was a
minor, informed consent was obtained from the subject’s
legal guardian. In subjects aged 12 to 17 years, informed
assent was obtained.
Technique for obtaining BALF
BALF was obtained in the following manner. After in-
duction of general anesthesia, a flexible bronchoscope
was passed into the airway via an endotracheal tube or
laryngeal mask airway. Lidocaine was placed at both the
vocal cords and carina. The area of lavage varied, and
was selected by the pulmonologist performing the pro-
cedure. In general, lavage was performed in areas where
mucus had collected, in areas where infiltrate was seen
on chest x-ray or chest computed tomography scan (CT
scan) or from the right middle lobe. Typically three la-
vages were performed using sterile nonbacteriostatic
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quot consisted of 1 milliliter per kilogram of body
weight, with a maximum of 30 milliliters of normal sa-
line per lavage. After BALF collection, any excess fluid
not required for clinical laboratory testing was processed
for research.
Collected BALF was processed in a standard manner. It
was initially centrifuged for 10 minutes at 1200 revolutions
per minute (rpms) and 4 degrees Celsius. The pellet was
saved, and the supernatant was spun again for 20 minutes
at 4700 rpms and 4 degrees Celsius. The second pellet was
saved. This supernatant was split in half, with half stored
0.5 mL aliquots at −70 degrees Celsius. The other half of
the supernatant was treated with the protease inhibitors
Phenylmethylsulfonyl Fluoride (PMSF), and Ethylenedia-
minetetra acetic acid (EDTA) to inhibit protease activity.
The samples are frozen at −70°C for further study.
Bronchoalveolar lavage cell counts and differentials
Collected BALF was centrifuged to separate fluid from
cells. The cell pellet was resuspended and cell counts and
differentials were determined. Results were expressed as
viable cells/mL of lavage fluid.
Microbiology
Bacterial culture and viral culture, Direct Fluorescent-
Antibody (DFA; until 2007) and polymerase chain reac-
tion (PCR after 2007) were performed on the collected
BALF. Common organisms were screened for, including
Staphylococcus and Streptococcal species, Haemophilus
influenzae, Moraxella catarrhalis, respiratory syncytial vi-
rus, influenza A and B, parainfluenza 1, 2, and 3, and rhi-
noviruses. Human metapneumovirus has been screened
for since 2007.
Normalization factors
Normalization of BALF was done as recommended by
consensus guidelines to report the percentage of volume
recovered compared to volume instilled. The BALF re-
covered was required to be at least 30% of the volume
instilled [15-17].
Cytokine analysis
Cytokine profiles were analyzed using the Fluorokine® Mul-
tiAnalyte Profiling (MAP) Cytokine Assay (R&D systems)
and the Luminex® 200™ analyzer, which measures multiple
analytes in a 50 microliter aliquot of processed BALF. This
system is a dual laser, flow-based sorting and detection
platform, which uses analyte-specific antibodies pre-coated
onto color-coded microparticles to measure 1–18 possible
cytokines. Microparticles are read using the Luminex 200
analyzer. One laser is microparticle-specific and deter-
mines which cytokine is being detected. The other laser de-
termines the magnitude of the phycoerythrin-derivedsignal, which is in direct proportion to the amount of ana-
lyte bound. The individual cytokines are quantified against
an 8-point calibration curve run with each plate.
Statistical analysis
Descriptive statistics were calculated using medians,
ranges, and interquartile ranges (IQR) where specified,
for continuous variables and percentages for categorical
variables. Kruskal – Wallis nonparametric tests were
used to compare cytokine values across the four disease
groups. Pairwise comparisons from nonparametric tests
were completed if the overall p-value comparing all 4
groups was < 0.05. Nonparametric canonical discrimin-
ant analysis (CDA) was performed to study the differ-
ences between groups with respect to all BALF variables
simultaneously. CDA is a multivariate method similar to
Principal Component Analysis (PCA) yet differs in that
we have prior knowledge of the groups. A normal kernel
density with a radius of 0.4 and the individual within-
group covariance matrices were specified for the CDA.
Crossvalidation was used to estimate classification error
rates. All analyses were performed using SAS version 9.3
software (SAS Institute Inc.: Cary, NC, 2011).
Results
Subject population
BALF samples from 41 patients with 8 different clinical
diagnoses were included in this investigation. The dis-
ease groups consisted of 22 NEHI subjects, 6 FB subjects
and disease controls including 7 CF disease controls,
and 6 non-CF disease controls (2 Bronchiolitis Obliter-
ans, 1 Primary Ciliary Dyskinesia, 1 recurrent aspiration,
1 non-cystic fibrosis bronchiectasis and 1 immunodefi-
ciency). The median age for the subjects at the time of
BALF collection was 1.5 years ranging between 1 month
and 11 years old; the CF group had slightly older sub-
jects. The CF and non-CF disease controls tended to be
mostly males, while the NEHI and FB groups consisted
of a more even gender mix. BALF volume percent
returned was similar across groups. Forty-two percent of
BALF samples had positive cultures. As expected the CF
group had the highest percentage of positive cultures
(86%) followed by the FB (50%) and NEHI (32%)
(Table 1).
Cell count and differential
The absolute number of BALF WBCs in NEHI was sig-
nificantly lower compared to all other groups but higher
than historical normal levels reported in the literature
[13] (Figure 1). The percentage of BALF neutrophils in
NEHI was also significantly lower compared to all other
groups. Conversely, CF had the highest levels of BALF
neutrophils across all groups (p-value <0.01). The per-
centage of BALF alveolar macrophages in NEHI was
Table 1 Subject demographics
NEHI (N = 22) FB (N = 6) CF (N = 7) Non-CF DC (N = 6)
Age at BAL in years, med
(min - max)
1 (0.1 - 6) 4 (1–11) 2 (1–6) 6 (0.3 - 9)
Male, N (%) 13 (59%) 3 (50%) 5 (71%) 4 (67%)
Volume percent returned,
med (min - max)




7 (32%) 3 (50%) 6 (86%) 1 (17%)
Types of pathogens Staphylococcus aureus (2) Haemophilus influenzae (2) Staphylococcus aureus (2) Oxidase negative non-lactose
fermenter (1)












Virus CMV (1) CMV (1)
Human Metapneumovirus (1)
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age of lymphocytes and eosinophils were not dramatic-
ally different between groups (Table 2).
Cytokine analyses
The following list of cytokines were significantly different
between the four disease groups; IL-1β, IL-8, MIP-1β,
MCP-1 and IL-6 (Table 3). In NEHI, IL-1β, IL-8 and MIP-
1β levels were considerably lower (the 75th percentile was
less than the median) than in both disease controls andFigure 1 Comparison of WBC and neutrophil counts across disease g
(A) and Neutrophil counts (B) across the 4 disease groups. The middle line
percentiles; the whiskers are drawn from the box to the most extreme poin
is marked with a point. The horizontal reference line and shaded area corre
from previously published data.FB. In FB, IL-1ra, VEGF and G-CSF levels were noticeably
higher (the 25th percentile was greater than the median)
than in both disease controls and NEHI (Figure 2A, 2B).
IL-6 was elevated in both CF and FB. VEGF, G-CSF, and
GM-CSF levels between groups did not differ dramatically.
Within the NEHI group of patients, cytokine levels were
investigated between biopsy proven (n =11) and NEHI
syndrome (n =11) patients, culture positive/negative classi-
fication, as well as change with age. These preliminary
evaluations did not yield striking differences or trends.roups. Boxplots displaying the distribution of absolute WBC counts
corresponds to the median; the box indicates the 25th and 75th
t within 1.5 interquartile ranges and any value more extreme than this
spond to the median and normal range of values in healthy patients













WBC 173 (88, 236) 761 (238, 1070) 650 (191, 1200) 500 (287, 1150) 0.02
RBC 16 (2, 40) 175 (61, 267) 33 (7, 1100) 150.5 (22, 326) 0.07
Segs % 2.5 (1, 5) 10 (2, 43) 67 (32, 79) 13 (3, 34) <.01
EOS % 0 (0, 0) 0.5 (0, 1) 0 (0, 0) 0 (0, 1) 0.44
Lymphocytes % 7 (2, 10) 7.5 (2, 15) 1 (0, 3) 9 (5, 11) 0.07
Macrophages & Monos % 84 (76, 90) 77 (43, 88) 30 (14, 61) 63 (55, 86) <.01
Epithelium % 1.5 (0, 6) 0 (0, 1) 0 (0, 2) 3.5 (0, 9) 0.21
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CBC and cytokine measurements which best discrimi-
nated between the four disease groups. The first two
components cumulatively explained 89% of the group
differences. The first component corresponds to the lin-
ear combination which explains most of the variability
across groups, the second component explains most of
the variability that remains after the first component,
and so on. The magnitude of the factor loadings (corre-
lations with components) for each variable indicate how
much weight that variable was given in the component.
The first component was highly positively correlated
with IL-1β, TNF-α, number of red blood cells (RBC), IL-
8 and percentage of Neutrophils (Segs %) (Figure 3A).
Higher values of these variables correspond to higher com-
ponent values which are associated with CF (Figure 3B).
Percentage of lymphocytes (Lymphs %), percentage of Mo-
nocytes and Macrophages (monos_macs), percentage of
eosinophils (EOS %), G-CSF and VEGF were highly nega-
tively correlated with the first component and higher
values for these variables were associated with FB. The







IL-1β1 2.1 (0.7, 2.5) 7.0 (2.5, 10.1)
IL-1ra1 449.8 (306.6, 663.2) 1558.9 (885.9, 1843.1)
IL-61 2.0 (1.0, 4.7) 9.7 (3.3, 16.5)
IL-81 35.5 (14.5, 71.7) 171.3 (20.4, 477.7)
G CSF 13.2 (6.1, 27.9) 33.5 (21.8, 48.6)
GM CSF 4.0 (1.8, 6.0) 4.0 (1.0, 6.0)
MCP 11 27.6 (19.6, 49.6) 56.1 (51.9, 113.2)
MIP 1β1 7.7 (4.4, 20.0) 22.8 (15.4, 55.3)
TNF α 0.8 (0.6, 2.0) 1.7 (1.0, 2.0)
VEGF 182.1 (89.3, 317.5) 270.5 (254.7, 486.6)
1Significant difference (p < 0.05) observed between NEHI and FB.IL-6, and a strong negative correlation with percentage
of epithelial cells (epithelium %). This second compo-
nent separated the FB and CF groups from the NEHI
and DC groups, where FB and CF had higher IL-6 and
NEHI and DC had a higher percentage of epithelium
cells (Figure 3A, 3B). All patient samples were correctly
classified into their corresponding disease groups by
cross-validation.
Discussion
ChILD diseases are rare, frequently difficult to diagnose and
create hardships for children and their families. A high
index of suspicion and a complete evaluation are needed to
correctly identify these diseases, as they often have similar
signs and symptoms at presentation like NEHI and FB. Al-
though no deaths have been reported from NEHI, NEHI pa-
tients may require oxygen use for years and aggressive
nutritional supplementation. Glucocorticoid therapy has not
been found to be effective and currently is not routinely rec-
ommended [4,5]. At our center, NEHI is one of the most
common chILD diseases treated. Other chILD disorders can







27.7 (4.7, 85.9) 2.7 (2.5, 7.2) <0.01
511.8 (308.7, 1567.1) 369.3 (278.6, 1107.4) 0.10
9.2 (4.6, 10.6) 2.8 (2.0, 8.4) 0.04
705.2 (521.1, 1504.2) 120.0 (42.3, 306.6) <0.01
13.1 (7.9, 39.4) 8.0 (5.4, 34.5) 0.39
6.0 (4.0, 6.0) 1.1 (1.0, 6.0) 0.59
138.2 (43.9, 335.8) 21.1 (11.6, 84.8) 0.01
83.3 (36.0, 100.2) 31.9 (20.0, 140.3) <0.01
2.0 (2.0, 4.1) 1.4 (0.6, 2.7) 0.06
149.2 (64.2, 206.4) 79.6 (42.3, 159.4) 0.30
Figure 2 Comparison of cytokine levels across disease groups. Cytokine profiles identified in BALF of NEHI, FB, CF and Disease Controls all
values expressed as pg/mL. A) Shows quantities on the log scale for each cytokine by group with box whiskers. The cyokines are ordered by
overall median value. The middle line corresponds to the median; the ends of the box indicate the 25th and 75th percentiles; the whiskers are
drawn from the box to the most extreme point within 1.5 interquartile ranges and any value more extreme than this is marked with a point.
B) Patient specific cytokine profiles separately by group. Cytokine values within a subject are connected by lines.
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ventilation, lung transplantation, pulmonary hypertension,
and/or prolonged oxygen requirements. Patients in this
more severe group are routinely treated aggressively with
glucocorticoids and other immunosuppressive agents in
addition to supportive care [5,18]. Thus, a correct diagnosisFigure 3 Results from canonical discriminant analysis. Canonical Discrim
Analysis (PCA) yet differs in that we have prior knowledge of the groups. A)
two components which cumulatively explain 89% of the group differenc
are used to calculate the scores for each sample. B) A plot of the first t
group. The first two components result in good separation between dise
and disease controls which look similar.is critical to optimize and direct the treatment plan and
provide guidance for the family. New approaches to im-
prove diagnostic strategies are needed. Though prelimi-
nary in nature, our pilot data suggests biomarkers may
be identified in BALF and helpful in distinguishing NEHI
and FB from other airway diseases.inant Analysis is a multivariate method similar to Principal Component
displays the correlation between each BALF measurement and the first
es. This displays the weights attributed to each BALF variable which
wo component score values for each individual identified by disease
ase groups, the CF and FB groups are distinguished from the NEHI
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biopsy in patients with chronic or severe symptoms, al-
though the invasiveness of the procedure, physical dis-
comfort, surgical risks and need for hospitalization after
the procedure has increased interest in less invasive diag-
nostic modalities. Recently, patients with NEHI syndrome
have been diagnosed using clinical findings, CT scan, in-
fant pulmonary functions and negative findings on bron-
choscopy in some centers [19]. However, despite gains in
recognizing the classic clinical phenotype of NEHI, some
children present with atypical clinical phenotypes that
may require lung biopsy. There is also little understanding
of the underlying disease mechanism and limited thera-
peutic options to address years of morbidity for children
and their families with NEHI. Our data suggest that the
BALF in NEHI is significantly less inflammatory and dis-
tinctly different than other types of chILD diseases that
predominately involve the airways. These results would be
consistent with NEHI lung biopsy findings that show a
paucity of inflammation, in contrast to FB and other air-
ways diseases, and could reinforce the clinical practice of
limiting daily glucocorticoid and other immunomodula-
tory treatments in NEHI.
BALF samples from disease groups all contained poten-
tial bacterial pathogens with the CF group containing the
highest percent. Though NEHI had positive bacterial
cultures, the cell counts in the BALF did not appear in-
flammatory in nature. Furthermore one NEHI patient
without evidence of BALF inflammation had Pseudomonas
aeruginosa (non mucoid) and Serratia marcescens cul-
tured from the BALF. It may be that unlike CF patients
who had evidence of significant neutrophilia on BALF,
NEHI patients did not activate a response in the lower air-
ways with these bacteria or the majority of these bacteria
were from the upper airways.
Pulmonary neuroendocrine cells (PNECs) are innervated
cells located in the airways that are postulated to have
roles in lung development, oxygen sensation, dyspnea, in-
flammation, bronchoconstriction and vasodilatation [20].
They may increase in in other conditions besides NEHI,
including Bronchopulmonary dysplasia, Cystic Fibrosis,
Sudden Infant Death and Asthma [2,9]. They are also
known to produce chemically active amines and peptides
such as serotonin (5-HT), Bombesin/Gastrin releasing
peptide (GRP), calcitonin gene-related peptide (CGRP),
Substance P (SP) and neuronal markers including neuron
specific enolase (NSE) [21]. Thus, we strongly hypothesize
that biomarker signals other than pro-inflammatory cyto-
kines and chemokines may be distinguishing and provide
more insight into the pathogenesis of NEHI. These studies
are clearly warranted using more advanced discovery gen-
omic and proteomic approaches with expanded panels of
proteins to investigate BALF and serum. Though our
current study lacked the ability to measure these bioactivePNEC substances, our data suggest that these substances
are not activating a pro-inflammatory cytokine response in
NEHI. Elucidating disease mechanisms involved in NEHI
may also be important to further our understanding in
other diseases associated with PNEC abnormalities.
Within the adult interstitial lung disease (ILD) litera-
ture, several groups have detailed different BALF cellular
profiles showing increased lymphocytosis in Non- spe-
cific Interstitial Pneumonitis (NSIP) and Cryptogenic
Organizing Pneumonia (COP) compared to Usual Inter-
stitial Pneumonia (UIP); in contrast, neutrophils were el-
evated in UIP in comparison to NSIP and COP [14,22].
Cytokine and chemokine profiles have also been re-
ported in BALF of adult ILD patients to include eleva-
tions of IL-ra, VEGF, IL-8, ENA-78 levels compared to
controls. A group of eight proteins has recently been
propose as disease progression serum markers in Idio-
pathic Pulmonary Fibrosis (IPF): KL-6, surfactant protein
A, and MMP-7, CCL-18, S100A12, IL-8, ICAM-1 and
VCAM-1 [14,18,22-25]. Unfortunately, studies of BALF
and serum biomarkers in children with chILD lag be-
hind. No BALF cytokine data exists in the chILD litera-
ture, although Fan and colleagues recently published
their use of serum KL-6 in differentiating NEHI from
patients with surfactant dysfunction mutations [26]. Un-
fortunately, the KL-6 assay is not commercially available
in the United States. Our results add to the literature as
the first to examine BALF cytokines and chemokines in
chILD.
The finding of increased inflammatory cytokines in FB,
specifically IL-6, MCP-1, and IL-1ra may highlight the role
of these cytokines in the formation of the germinal centers
near the airway that characterize FB. Lymphocytic disor-
ders of the lung, such as FB, have been proposed to have
an immune or autoimmune etiology, though cases in chil-
dren are frequently idiopathic at the time of presentation
[13]. The association of IL-6 with autoimmune disease
like rheumatoid arthritis and transplantation rejection
may lend credence to this as a potential disease pathway
in FB [27]. Furthermore, distinguishing FB from NEHI is
also clinically relevant as some in the chILD community
speculate that NEHI and FB may be from the same
spectrum of disease and clinically patients can look very
similar. Finally, IL-6 may be a potential therapeutic target
as humanized anti–IL-6 receptor antibody, tocilizumab,
has been used to target the IL-6 pathway in rheumatoid
arthritis, Castleman disease, and systemic lupus erythe-
matosus [27]. Further studies are indicated of the IL-6
pathway and chILD, especially those with a potential auto-
immune etiology.
The BALF results in our CF group were consistent
with previous publications showing elevations in WBCs,
predominately neutrophils, and increased levels of tumor
necrosis factor (TNF)- α, interleukin (IL)-1β, IL-6, IL-8,
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CSF), and granulocyte colony– stimulating factor (GCSF)
in airway secretions compared to controls [28]. Recently
elevated levels of CC chemokines MCP-1(CCL2), MIP-1α,
(CCL3), MIP-1β and (CCL4) and MIP-3α (CCL20) were
reported in BALF of young children with CF with little ap-
parent lung disease or infection [29]. Our data also shows
elevations in MIP-1β and MCP-1 in our small sample of
CF subjects with limited BALF infections.
This study has inherent limitations related to small
sample size, retrospective study design, and biased pa-
tient selection from a single center where not all patients
with these diagnoses underwent BAL due to the clinical
situation for each subject. However, in rare disease, small
sample sizes to evaluate pilot data are common before
large sample collection from multiple institutions can be
obtained to further validate preliminary findings. Despite
these limitations, the NEHI samples set of 22 BALF is
one of the largest samples of patients with NEHI pub-
lished and this data represents the first set of distin-
guishing cytokine measured in chILD.
Conclusions
This study demonstrates the potential value of BALF
biomarker analysis for diagnosis and insight into disease
pathogenesis for chILD, especially NEHI and FB. Further
study is needed to validate these findings and extend our
BALF studies using more advanced genomic and prote-
omic molecular technology approaches.
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PMSF: Phenylmethylsulfonyl fluoride; PNEC: Pulmonary neuroendocrine cell;
RBC: Red blood cells; SIDS: Sudden infant death syndrome; SP: Surfactant
protein; TNF-α: Tumor necrosis factor alpha; TTF: Thyroid transcription factor;
VEGF: Vascular endothelial growth factor; WBC: White blood cell.
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